

THE National Investor



March 5, 2024

You can get information anywhere. Here, you get KNOWLEDGE.

Vol. 29 - No. 4

NEW RECOMMENDATION - BETTER LIFE PHARMA (CSE-BETR; OTCQB-BETRF)

Yesterday's (March 4) close -- C\$0.09/share, or approx. US\$0.067/share

I have been following BetterLife for going on a year now, after having first received a very solid introduction to the company from a colleague.

Though not the craze *at the moment* that obesity drugs are, BETR has some fascinating science (which I've spent a fair bit of time in a couple lengthy talks with management to come to understand) to deal with myriad mental health issues and related problems/maladies.

As you will read among many other things at BETR's specific [INVESTOR RELATIONS PAGE](#), the company recently raised some money to move closer to an IND filing with the FDA to start human clinical trials of what is called BETR-001; a "psychedelic" whose story is as compelling as any compound I EVER heard of save for Sarepta Therapeutics' original Eteplirsen.

And I.M.O. it has the same potential to disrupt an entire *set* of indications.

Better Life Pharma is added to my roster of Speculative companies as an immediate BUY. I will be adding more color in a follow-up and broader profile in the days ahead.

** The preceding is taken from an email alert to the paid Membership of The National Investor of March 5, 2024*

Don't forget to follow my thoughts, focus, occasional news on covered companies AND MORE pretty much *daily* !!!

- * On Twitter, at <https://twitter.com/NatInvestor>
- * On Facebook at <https://www.facebook.com/TheNationalInvestor>
- * On Linked In at <https://www.linkedin.com/in/chris-temple-1a482020/>
- * On my You Tube channel, at <https://www.youtube.com/c/ChrisTemple> (MAKE SURE TO *SUBSCRIBE!*)

The National Investor is published and is e-mailed to subscribers from chris@nationalinvestor.com. The Editor/Publisher, Christopher L. Temple may be personally addressed at this address, or at our physical address, which is -- National Investor Publishing, P.O. Box 1257, Saint Augustine, FL 32085. The Internet web site can be accessed at <https://nationalinvestor.com/>. **Subscription Rates:** Go to <https://www.nationalinvestor.com/subscribe-renew/> for Membership options for all our content/recommendations. **Trial Rate:** \$75 for a one-time, 3-month full-service trial. Current sample may be obtained upon request (for first-time inquirers ONLY.)

The information contained herein is conscientiously compiled and is correct and accurate to the best of the Editor's knowledge. Commentary, opinion, suggestions and recommendations are of a general nature that are collectively deemed to be of potential interest and value to readers/investors. Opinions that are expressed herein are subject to change without notice, though our best efforts will be made to convey such changed opinions to then-current paid subscribers. We take due care to properly represent and to transcribe accurately any quotes, attributions or comments of others. No opinions or recommendations can be guaranteed. The Editor may have positions in some securities discussed. Subscribers are encouraged to investigate any situation or recommendation further before investing. The Editor receives no undisclosed kickbacks, fees, commissions, gratuities, honoraria or other emoluments from any companies, brokers or vendors discussed herein in exchange for his recommendation of them. All rights reserved. Copying or redistributing this proprietary information by any means without prior written permission is prohibited.

No Offers being made to sell securities: within the above context, we, in part, make suggestions to readers/investors regarding markets, sectors, stocks and other financial investments. These are to be deemed informational in purpose. None of the content of this newsletter is to be considered as an offer to sell or a solicitation of an offer to buy any security. Readers/investors should be aware that the securities, investments and/or strategies mentioned herein, if any, contain varying degrees of risk for loss of principal. Investors are advised to seek the counsel of a competent financial adviser or other professional for utilizing these or any other investment strategies or purchasing or selling any securities mentioned. Chris Temple is not registered with the United States Securities and Exchange Commission (the "SEC"): as a "broker-dealer" under the Exchange Act, as an "investment adviser" under the Investment Advisers Act of 1940, or in any other capacity. He is also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.

Notice regarding forward-looking statements: certain statements and commentary in this publication may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 or other applicable laws in the U.S. or Canada. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of a particular company or industry to be materially different from what may be suggested herein. We caution readers/investors that any forward-looking statements made herein are not guarantees of any future performance, and that actual results may differ materially from those in forward-looking statements made herein. **Copyright issues or unintentional/inadvertent infringement:** In compiling information for this publication the Editor regularly uses, quotes or mentions research, graphics content or other material of others, whether supplied directly or indirectly. Additionally he makes use of the vast amount of such information available on the Internet or in the public domain. Proper care is exercised to not improperly use information protected by copyright, to use information without prior permission, to use information or work intended for a specific audience or to use others' information or work of a proprietary nature that was not intended to be already publicly disseminated. If you believe that your work has been used or copied in such a manner as to represent a copyright infringement, please notify the Editor at the contact information above so that the situation can be promptly addressed and resolved.